Bharat Immunological Biological Corporation Ltd vs Natco Pharma Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Bharat Immunological & Biological Corporation Ltd is ₹ 17.33 as of 05 May 15:30 . The P/E Ratio of Bharat Immunological & Biological Corporation Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Natco Pharma Ltd changed from 34.2 on March 2021 to 7.6 on March 2025 . This represents a CAGR of -25.98% over 5 years The Market Cap of Bharat Immunological & Biological Corporation Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Market Cap of Natco Pharma Ltd changed from ₹ 15045 crore on March 2021 to ₹ 14287 crore on March 2025 . This represents a CAGR of -1.03% over 5 years The revenue of Bharat Immunological & Biological Corporation Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Natco Pharma Ltd for the Dec '25 is ₹ 705.4 crore as compare to the Sep '25 revenue of ₹ 1463 crore. This represent the decline of -51.78% The ebitda of Bharat Immunological & Biological Corporation Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Natco Pharma Ltd for the Dec '25 is ₹ 216.8 crore as compare to the Sep '25 ebitda of ₹ 679.2 crore. This represent the decline of -68.08% The net profit of Bharat Immunological & Biological Corporation Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The net profit of Natco Pharma Ltd changed from ₹ 668.5 crore to ₹ 140.4 crore over 7 quarters. This represents a CAGR of -59.01% The Dividend Payout of Bharat Immunological & Biological Corporation Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Natco Pharma Ltd changed from 30.96 % on March 2021 to 5.8 % on March 2025 . This represents a CAGR of -28.46% over 5 years .

About Bharat Immunological & Biological Corporation Ltd

The Bharat Immunologicals and Biologicals Corporation Limited (BIBCOL) is a Central Public Sector Unit, under the Department of Biotechnology, Ministry of Science and Technology.
BIBCOL was incorporated in 1989.
The Company is engaged in the manufacture of Oral Polio Vaccine (OPV) , Zinc Tablets and Diarehha management Kit and BIB Sweet Tablets. The company's manufacturing unit is located in Bulandshahr Dist., Uttar Pradesh.
BIBCL installed a plant of 100 mln units.
Commercial production of the OPV started from Jan'96. The company has received firm orders for supply of OPV from the Ministry of Health and Family Welfare, Government of India, for use in the national immunisation programme.

About Natco Pharma Ltd

Natco Pharma Limited was originally incorporated on 19 September 1981 as private limited company as 'Natco Fine Pharmaceuticals Private Limited'.
The name of the company was changed to Natco Pharma Limited and a fresh certificate of incorporation dated 30 December 1994 issued by the RoC, Andhra Pradesh. Natco Pharma is a vertically integrated and R&D focused pharmaceutical company that specialises in development, manufacturing and marketing of Finished Dosage Formulations (FDF) and Active Pharmaceutical Ingredients (APIs).
The Company's focus is primarily on niche therapeutic areas and complex products.
It sells products in over 40 countries.
FDF products are sold in the United States, India, Europe and the rest of the world (RoW).

FAQs for the comparison of Bharat Immunological & Biological Corporation Ltd and Natco Pharma Ltd

Which company has a larger market capitalization, Bharat Immunological & Biological Corporation Ltd or Natco Pharma Ltd?

Market cap of Bharat Immunological & Biological Corporation Ltd is 74 Cr while Market cap of Natco Pharma Ltd is 20,131 Cr

What are the key factors driving the stock performance of Bharat Immunological & Biological Corporation Ltd and Natco Pharma Ltd?

The stock performance of Bharat Immunological & Biological Corporation Ltd and Natco Pharma Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Bharat Immunological & Biological Corporation Ltd and Natco Pharma Ltd?

As of May 5, 2026, the Bharat Immunological & Biological Corporation Ltd stock price is INR ₹17.33. On the other hand, Natco Pharma Ltd stock price is INR ₹1124.0.

How do dividend payouts of Bharat Immunological & Biological Corporation Ltd and Natco Pharma Ltd compare?

To compare the dividend payouts of Bharat Immunological & Biological Corporation Ltd and Natco Pharma Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.